Definitions

• the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non- hygroscopic sulfate salt and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non- hygroscopic sulfate salt alone or in combination with other compounds.
• the present invention also relates to compositions containing said 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline, stoichiometrically defined and non-hygroscopic sulfate salt and inert carrier material which are useful as urotensin-ll antagonist.
• An object of the present invention is to provide 1-[2-(4-benzyl-4-hydroxy-piperidin- 1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I in a stoichiometrically defined and non-hygroscopic crystalline form which shows improved properties suitable for a pharmaceutical product, pharmaceutical preparations, production in large scale and storage.
• the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea of formula I as a sulfate trihydrate.
• a sulfate salt of 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I is described by [Martine Clozel et. al., J Pharmacol Exp Ther. 2004; DOI:10.1124/jpet.104.068320] but no procedure for its preparation has been disclosed.
• the present invention also relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as a sulfate dihydrate.
• the present invention also relates to a process for preparing 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt which process comprises
• 3-(2-methyl-quinolin-4-yl)-urea sulfate hydrate by stirring in water, in a mixture of water and an organic solvent, or by exposure to an atmosphere of controlled relative humidity.
• the sulfate salt of 1 -[2-(4-benzyl-4-hydroxy-piperidin-1 -yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I is 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin- 4-yl)-urea sulfate trihydrate.
• the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt obtainable by the process mentioned above.
• compositions comprising 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I as stoichiometrically defined and non-hygroscopic sulfate salt as mentioned above and inert carrier material
• the present invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above and their use as medicaments.
• 1-[2-(4-benzyl- 4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as described above can be used for treatment of diseases which are associated with an increase in vasoconstriction, proliferation or other disease states associated with the actions of urotensin II.
• diseases are hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, asthma, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis.
• They can also be used for prevention of restenosis after balloon or stent angioplasty, for the treatment of cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addictions, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, neurodegenerative diseases, as well as other diseases related to a dysregulation of urotensin Il or urotensin Il receptors.
• compositions may be administered in enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions, in nasal form like sprays and aerosols, or rectally in form of suppositories.
• enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions, in nasal form like sprays and aerosols, or rectally in form of suppositories.
• 1-[2-(4-Benzyl-4-hydroxy- piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above may also be administered in intramuscular, parenteral or intravenous form, e.g. in form of injectable solutions.
• compositions may contain 1-[2-(4-benzyl-4-hydroxy- piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salts as mentioned above in combination with inorganic and/or organic excipients, which are usual in the pharmaceutical industry, like lactose, maize or derivatives thereof, talcum, stearic acid or salts of these materials.
• vegetable oils, waxes, fats, liquid or half-liquid polyols etc. may be used.
• solutions and sirups e.g. water, polyols, saccharose, glucose etc. are used.
• injectables are prepared by using e.g. water, polyols, alcohols, glycerin, vegetable oils, lecithin, liposomes etc.
• Suppositories are prepared by using natural or hydrogenated oils, waxes, fatty acids (fats), liquid or half-liquid polyols etc.
• compositions may contain in addition preservatives, stabilisation improving substances, viscosity improving or regulating substances, solubility improving substances, sweeteners, dyes, taste improving compounds, salts to change the osmotic pressure, buffer, anti-oxidants etc.
• ⁇ - and ⁇ -blockers like phentolamine, phenoxybenzamine, atenolol, propranolol, timolol, metoprolol, carteolol, carvedilol, etc.; with vasodilators like hydralazine, minoxidil, diazoxide, flosequinan, etc.; with calcium-antagonists like diltiazem, nicardipine, nimodipine, verapamil, nifedipine, etc.; with angiotensin converting enzyme-inhibitors like cilazapril, captopril, enalapril, lisinopril etc.; with potassium channel activators like pinacidil, chromakalim, etc.; with angiotensin receptor antagonists like losartan, valsartan, candesartan, irbesartan, eprosartan, telmisartan,
• the dosage may vary within wide limits but should be adapted to the specific situation.
• the dosage given daily in oral form should be between about 3 mg and about 3 g, preferably between about 5 mg and about 1 g, especially preferred between 10 mg and 300 mg, per adult with a body weight of about 70 kg.
• the dosage should be administered preferably in 1 to 3 doses of equal weight per day. As usual children should receive lower doses which are adapted to body weight and age.
• the present invention also relates to compositions containing amorphous parts of
• crystal or crystalline is used to describe the part of crystalline material compared to amorphous material and is estimated eg. by the line shape and the background intensity in X-ray diffraction patterns.
• a crystallinity of 90% to 100% is estimated.
• the crystallinity is within the range of 92 % to 100 %.
• the crystallinity is within the range of 95 % to 100 %.
• organic solvents means solvents or mixtures of solvents, such as Ci -4 -alkanol (CH 3 OH, C 2 H 5 OH, n-C 3 H 7 OH, 1-C 3 H 7 OH, n-C 4 H 9 OH, J-C 4 H 9 OH, t-C 4 H 9 OH), ketones (acetone, ethylmethylketone, methylisobutylketone), ethers (diethylether, tetrahydrofurane, 1 ,4-dioxane, methyl- tert. butylether) or acetonitrile.
• Ci -4 -alkanol CH 3 OH, C 2 H 5 OH, n-C 3 H 7 OH, 1-C 3 H 7 OH, n-C 4 H 9 OH, J-C 4 H 9 OH, t-C 4 H 9 OH
• ketones acetone, ethylmethylketone, methylisobutyl
• organic solvents are CH 3 OH, C 2 H 5 OH, n-CsHyOH, J-CaH 7 OH and acetone. Most preferred "organic solvents” are CH 3 OH, C 2 H 5 OH, J-C 3 H 7 OH and acetone.
• solution of sulfuric acid means solutions of sulfuric acid in water, or a solution of sulfuric acid in a mixture of water and an organic solvent., preferably aqueous solutions.
• Sulfuric acid solutions are in the concentration range of 0.01 to 10 mol/L, more preferred in the concentration range of 0.1 to 5 mol/L, most preferred in the concentration range of 0.2 to
• crystalline form means crystalline compounds as described before that contain 1 [2 (4 benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea of Formula I, sulfuric acid and water in a defined molecular ratio X:Y:Z, whereby X and Y represent 1 , and Z represents the numbers 0 to 4. In a more preferred embodiment Z represents the numbers 0 to 3. In the most preferred embodiment Z represents the numbers 2 or 3.
• X-ray diffraction patterns were recorded on a Bruker D5000, using a Cu- Kaip h a (1.5418 A) source, a 4OkV - 3OmA generator, in a range of 3 et 40° (2theta).
• DVS is performed as gravimetric measurement (10 - 30 mg of sample), at a given temperature, under controlled relative humidity. Measurements are performed on a
• SMS Surface Measurement Sytems
• RH relative humidity
• Figure 1 shows the XRD-diffraction pattern of the compound described in Example 1.
• Table 1 summarizes the peaks and their intensity.
• Example 1 Type 2Th/Th locked - Start : 3.000° - End : 40.000° - Step : 0.020° - Step time : 1 s - Temp. : 25°C (room temperature) - Time Started : 3 s - 2-Theta : 3.000° - Theta : 1.500° - Phi : 0.00° DIF - Y : 77.31 % - d x by : 1.- WL : 1.54056 - 0-
• Table 2 summarizes the results of two cycles (0 to 85 % relative humidity) in a DVS measurement (4O 0 C) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate described in Example 1.
• Table 2 DVS data of the compound described in Example 1
• the formed precipitate is filtered, washed with cooled CH 3 OH (- 5°C, 54 L) and dried under a stream of nitrogen provide 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I sulfate as a non-defined hydrate.
• a slurry of the so obtained salt in H 2 O (16.2% w/w) is stirred for 3 days at 25°C. Filtration and drying at 30 0 C under a wet stream of nitrogen (50% RH) provides the title compound.
• Figure 2 shows the XRD-diffraction pattern of the compound described in Example 2.
• Table 3 summarizes the peaks and their intensity.
• Example 2 Type 2Th/Th locked - Start : 3.000° - End : 40.000° - Step : 0.020° - Step time : 1 s - Temp. : 30°C - Time Started : 3 s - 2-Theta : 3.000° - Theta : 1.500° - Phi : 0.00° - Aux1 : 0.0 DIF - Y : 77.08 % - d x by : 1.- WL : 1.54056 - 0-
• Table 4 summarizes the results of three cycles (0 to 85 % relative humidity) in a DVS measurement (25°C) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate described in Example 2.
• the formed precipitate is filtered, washed with cooled CH 3 OH (- 5°C, 54 L) and dried under a stream of nitrogen provide 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)- ethyl]-3-(2-methyl-quinolin-4-yl)-urea of formula I sulfate as a non-defined hydrate.
• the so obtained salt is exposed to humid atmosphere (>70 % RH) at 25 0 C to provide the title compound.
• Figure 3 shows the XRD-diffraction pattern of the compound described in Example 3.
• Table 5 summarizes the peaks and their intensity.
• Example 3 Type 2Th/Th locked - Start : 4.010° - End : 40.010° - Step : 0.020° - Step time : 1 s - Temp. : 25 0 C (room temperature) - Time Started : 0 s - 2-Theta : 4.010° DIF - Y : 79.17 % - d x by : 1.- WL : 1.54056 - 0-
• the wet seed used in the above procedure is prepared by mixing 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea sulfate trihydrate (Example 1 , 104 g) with a saturated solution (421 g) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)- urea sulfate trihydrate (Example 1 , 73.9 g) in aqueous ethanol (50 % VWW, 81O g).
• the obtained mixture is maintained at 50 0 C for about 15 minutes, then it is cooled to 0 0 C with a cooling rate of 15°C/h and maintained at this temperature for least 1 hour before filtration and washing with aqueous ethanol (50 % W/W, 3 kg).
• the solid is dried in a conductive agitated dryer at a temperature of 35 ⁇ 3°C under a wet stream of nitrogen (45+5% RH), optionally under stirring (max. 70 rpm) in case the cake humidity is below 25%, to provide the title compound with a purity of 99.8% with a yield of approximately 94%.
• the wet seed used in the above procedure is added in two shots and is prepared by mixing 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate (Example 1 , 6.5 g) with a saturated solution (13.9 g for the first shot, plus 15.6 g for subsequent rinsing and second shot) of 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]- 3-(2-methyl-quinolin-4-yl)-urea sulfate trihydrate (Example 1 , 7.0 g) in aqueous ethanol (50 % W/W, 50.0 g) for about 2 minutes.
• the first shot of wet seed is prepared at least 5 minutes before use to ensure that the seed is correctly wetted.

Landscapes

• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=38115910

Family Applications (1)

Country Status (1)

Citations (1)

• 2005
  • 2005-10-11 EP EP05792250A patent/EP1802604A1/de not_active Withdrawn

Patent Citations (1)

Non-Patent Citations (1)

Similar Documents

Legal Events